No Data
No Data
Express News | Amex Halt Add Info Lst 0.840000
CEL-SCI Announced Multikine Demonstrates Tumor Regression Pre-Surgery In 3 Weeks; FDA Approves 212-Person Study With 73% Survival Rate Vs. 45% Control In Head And Neck Cancer
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
Watching CEL-SCI; Zacks Small-Cap Research Gives Stock $7 Price Valuation
Express News | CEL-SCI Corp: On November 13, Patricia B Prichep Has Assumed the Duties of Chief Financial and Operations Officer
CEL-SCI, FDA Agree on Phase 3 Trial Design for Cancer Drug
Unlock the Full List